Eikon Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
EIKN$6.13+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating Activities | ||
| Net loss | $(171,367) | $(173,454) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 10,343 | 7,998 |
| Stock-based compensation expense | 6,996 | 10,183 |
| Amortization of premiums and accretion of discounts on marketable securities | (1,216) | (3,281) |
| Amortization of operating lease right-of-use assets | (172) | 4,776 |
| Impairment of operating lease right-of-use assets | — | 10,275 |
| Impairment of property and equipment | — | 10,741 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,858) | (2,420) |
| Other assets | 2,717 | 103 |
| Accounts payable | 5,821 | (631) |
| Accrued expenses and other current liabilities | (4,923) | (702) |
| Operating lease liabilities | (5,100) | 44,465 |
| Other liabilities | 5,000 | 4,690 |
| Net cash used in operating activities | (154,759) | (87,257) |
| Investing Activities | ||
| Purchase of property and equipment | (513) | (44,074) |
| Purchase of marketable securities | (386,775) | (321,406) |
| Proceeds from maturities of marketable securities | 230,500 | 115,750 |
| Net cash used in investing activities | (156,788) | (249,730) |
| Financing Activities | ||
| Proceeds from issuance of common stock under stock plans | 302 | 550 |
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | — | 350,203 |
| Proceeds from initial public offering, net of issuance costs | 349,031 | — |
| Net cash provided by financing activities | 349,333 | 350,753 |
| Net increase in cash, cash equivalents and restricted cash | 37,786 | 13,766 |
| Cash, cash equivalents and restricted cash at beginning of period | 113,072 | 130,878 |
| Cash, cash equivalents and restricted cash at end of period | $150,858 | $144,644 |
| Cash, cash equivalents and restricted cash at end of period | ||
| Cash and cash equivalents | $142,613 | $136,564 |
| Restricted cash | 8,245 | 8,080 |
| Cash, cash equivalents and restricted cash at end of period | $150,858 | $144,644 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $8 | $12 |
| Cash paid for operating lease liabilities | 20,966 | 5,119 |
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $102 | $279 |
| Vesting of early exercised stock options and restricted common stock | 35 | 240 |
| Operating lease liabilities arising from obtaining right-of-use assets | — | (12,291) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.